TY - JOUR
T1 - Influence of transplanted dose of CD56 + cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors
AU - Yamasaki, S.
AU - Henzan, H.
AU - Ohno, Y.
AU - Yamanaka, T.
AU - Iino, T.
AU - Itou, Y.
AU - Kuroiwa, M.
AU - Maeda, M.
AU - Kawano, N.
AU - Kinukawa, N.
AU - Miyamoto, T.
AU - Nagafuji, K.
AU - Shimoda, K.
AU - Inaba, S.
AU - Hayashi, S.
AU - Taniguchi, S.
AU - Shibuya, T.
AU - Gondo, H.
AU - Otsuka, T.
AU - Harada, M.
PY - 2003/9
Y1 - 2003/9
N2 - We investigated effects of variations in the cellular composition of G-CSF-mobilized peripheral blood progenitor cell (G-PBPC) allografts on clinical outcomes of allogeneic PBPC transplantation. We retrospectively analyzed transplanted doses of various immunocompetent cells from 27 HLA-identical sibling donors in relation to engraftment, incidence of graft-versus-host disease (GVHD), and survival. Significant variability was documented in both absolute numbers and relative proportions of CD34+, CD2+, CD3+, CD4high+, CD4+25+, CD8high+, CD19+, CD56+, and CD56+16+ cells contained in these allografts. Stepwise Cox regression analysis revealed that the CD56+ cell dose was significantly inversely correlated with the incidence of GVHD. Thus, there was a significantly higher incidence of grade II acute GVHD in patients receiving a lower CD56+16+ cell dose (hazard ratio (HR) 0.0090; 95% confidence interval (CI), <0.00001-3.38; P=0.031), a higher incidence of chronic GVHD in those receiving allografts with a lower CD56+16+ to CD34+ ratio (HR <0.00001; 95% CI <0.00001-0.0007; P=0.0035), and a higher incidence of extensive chronic GVHD in those receiving allografts with a lower CD5 + to CD34+ ratio (HR <0.00001; 95% CI <0.00001-0.053; P=0.0083). These results suggest that CD56+ cells in G-PBPC allografts from HLA-identical sibling donors may play an important role in preventing the development of GVHD.
AB - We investigated effects of variations in the cellular composition of G-CSF-mobilized peripheral blood progenitor cell (G-PBPC) allografts on clinical outcomes of allogeneic PBPC transplantation. We retrospectively analyzed transplanted doses of various immunocompetent cells from 27 HLA-identical sibling donors in relation to engraftment, incidence of graft-versus-host disease (GVHD), and survival. Significant variability was documented in both absolute numbers and relative proportions of CD34+, CD2+, CD3+, CD4high+, CD4+25+, CD8high+, CD19+, CD56+, and CD56+16+ cells contained in these allografts. Stepwise Cox regression analysis revealed that the CD56+ cell dose was significantly inversely correlated with the incidence of GVHD. Thus, there was a significantly higher incidence of grade II acute GVHD in patients receiving a lower CD56+16+ cell dose (hazard ratio (HR) 0.0090; 95% confidence interval (CI), <0.00001-3.38; P=0.031), a higher incidence of chronic GVHD in those receiving allografts with a lower CD56+16+ to CD34+ ratio (HR <0.00001; 95% CI <0.00001-0.0007; P=0.0035), and a higher incidence of extensive chronic GVHD in those receiving allografts with a lower CD5 + to CD34+ ratio (HR <0.00001; 95% CI <0.00001-0.053; P=0.0083). These results suggest that CD56+ cells in G-PBPC allografts from HLA-identical sibling donors may play an important role in preventing the development of GVHD.
UR - http://www.scopus.com/inward/record.url?scp=10744225346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744225346&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1704165
DO - 10.1038/sj.bmt.1704165
M3 - Article
C2 - 12942097
AN - SCOPUS:10744225346
SN - 0268-3369
VL - 32
SP - 505
EP - 510
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -